Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Connolly, Stuart J., Crowther, Mark, Eikelboom, John W., Gibson, C. Michael, Curnutte, John T., Lawrence, John H., Yue, Patrick, Bronson, Michele D., Lu, Genmin, Conley, Pamela B., Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T., Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M., Pallin, Daniel J., Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M., Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/
https://ncbi.nlm.nih.gov/pubmed/30730782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares